Bristol-Myers Squibb Company (BMY) and Duke Translational Medicine Institute Form Strategic Relationship to Broaden Interactions  
2/28/2012 6:31:28 AM

PRINCETON, N.J. & DURHAM, N.C.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Duke Translational Medicine Institute (DTMI) today announced the formation of a strategic relationship to broaden interactions between the two organizations. The relationship builds on a decade of collaboration in cardiology, endocrinology, and oncology, and will extend into other therapeutic areas at all stages of development, fostering increased exchange between DTMI researchers, and Bristol-Myers Squibb scientists and project teams.